Advertisement

Topics

PellePharm, Inc Announces Topline Results From Phase II Study Of Topical Patidegib In Gorlin Syndrome Basal Cell Carcinomas And Third Closing Of A $20 Million Series B Financing

20:00 EDT 30 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: PellePharm, Inc Announces Topline Results From Phase II Study Of Topical Patidegib In Gorlin Syndrome Basal Cell Carcinomas And Third Closing Of A $20 Million Series B Financing

NEXT ARTICLE

More From BioPortfolio on "PellePharm, Inc Announces Topline Results From Phase II Study Of Topical Patidegib In Gorlin Syndrome Basal Cell Carcinomas And Third Closing Of A $20 Million Series B Financing"

Quick Search
Advertisement